APW
VKTX icon

Allied Private Wealth’s Viking Therapeutics VKTX Stock Holding History

Allied Private Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199 Buy
+5
New +$162 ﹤0.01% 867

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Allied Private Wealth's VKTX Position: Q2 2026 in Review

Allied Private Wealth opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 5 shares worth $199. The stake represents ﹤0.01% of the portfolio and ranks #867 among its holdings.

434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Allied Private Wealth held 5 shares of Viking Therapeutics worth $199 as of Q2 2026.
  • Viking Therapeutics was a new Allied Private Wealth position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Allied Private Wealth's portfolio in Q2 2026, its #867 holding.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Allied Private Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.